Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) — Net Asset Quality Index
Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) has a Net Asset Quality Index of 87.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥13.76 Billion minus total liabilities of CN¥1.77 Billion yields net assets of CN¥11.99 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Beijing Wantai Biological Pharmacy Enter (603392) financial obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Net Asset Quality Index Over Time (2013–2025)
This chart shows how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 87.1%, representing net assets of CN¥11.99 Billion against total assets of CN¥13.76 Billion CNY. For live market cap and overall valuation, see 603392 company net worth.
Annual Net Asset Quality Index for Beijing Wantai Biological Pharmacy Enterprise Co Ltd (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for Beijing Wantai Biological Pharmacy Enterprise Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check strategic asset allocation of Beijing Wantai Biological Pharmacy Enter to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 85.7% | CN¥12.03 Billion | CN¥14.04 Billion | CN¥2.01 Billion | ▲ +0.9 pp |
| 2024 | 84.7% | CN¥12.45 Billion | CN¥14.69 Billion | CN¥2.24 Billion | ▲ +2.8 pp |
| 2023 | 82.0% | CN¥12.88 Billion | CN¥15.71 Billion | CN¥2.83 Billion | ▲ +4.6 pp |
| 2022 | 77.4% | CN¥12.56 Billion | CN¥16.23 Billion | CN¥3.66 Billion | ▲ +12.7 pp |
| 2021 | 64.8% | CN¥4.56 Billion | CN¥7.05 Billion | CN¥2.48 Billion | ▼ -8.9 pp |
| 2020 | 73.6% | CN¥2.58 Billion | CN¥3.50 Billion | CN¥923.29 Million | ▲ +0.6 pp |
| 2019 | 73.0% | CN¥1.58 Billion | CN¥2.16 Billion | CN¥584.19 Million | ▼ -2.5 pp |
| 2018 | 75.5% | CN¥1.37 Billion | CN¥1.81 Billion | CN¥444.24 Million | ▲ +21.2 pp |
| 2017 | 54.3% | CN¥898.99 Million | CN¥1.66 Billion | CN¥756.80 Million | ▼ -11.7 pp |
| 2016 | 66.0% | CN¥959.70 Million | CN¥1.45 Billion | CN¥494.76 Million | ▲ +0.4 pp |
| 2015 | 65.6% | CN¥722.69 Million | CN¥1.10 Billion | CN¥378.93 Million | ▼ -6.4 pp |
| 2014 | 72.0% | CN¥580.32 Million | CN¥805.50 Million | CN¥225.19 Million | ▲ +9.1 pp |
| 2013 | 62.9% | CN¥382.06 Million | CN¥606.98 Million | CN¥224.92 Million | — |